From Yahoo Finance: 2025-05-12 12:42:00

HistoSonics secures major insurance coverage for histotripsy system, valued at $2.5bn. Blue Cross Blue Shield of Michigan enables treatment for liver tumors. FDA-approved Edison system offers non-invasive therapy for 4.5 million Michigan residents. HistoSonics achieves 90% local tumor control rate in liver cancer study, surpassing standard care. Expansion into kidney and pancreatic cancer treatment underway.

Edison system adopted at 50+ US medical centers, treating 1,500+ patients. CEO Mike Blue emphasizes importance of safe, non-invasive options for liver tumor patients. Acquisition rumors swirl around HistoSonics, with Medtronic, GE HealthCare, and Johnson & Johnson showing interest. J&J has previously invested in HistoSonics, latest through $102m Series D round in 2024.

HistoSonics’ milestone sets precedent for expanded histotripsy access in the US. Acquisition speculation grows as major medtech companies evaluate the company. Future expansion of histotripsy treatment options expected nationwide.



Read more at Yahoo Finance: HistoSonics secures first insurance coverage for histotripsy system